Showing results (91-100 of 430) with videos related to

Sort By:
Pageof 43
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
Circulation|June 28, 2006
Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trialScott D Solomon, Madeline M Rice, Kathleen A Jablonski, et al.
The New England Journal of Medicine|February 17, 2005
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma preventionScott D Solomon, John J V McMurray, Marc A Pfeffer, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Circulation|December 1, 2004
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) studyMariya P Tokmakova, Hicham Skali, Satish Kenchaiah, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|September 29, 2005
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM ProgramGary F Mitchell, J Malcolm O Arnold, Mark E Dunlap, et al.
European Journal of Heart Failure|March 1, 2014
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRTHicham Skali, Edward M Dwyer, Robert Goldstein, et al.
Pageof 43